Acceptability of Long-term Progestin-only Contraception in Europe

• Continuation rate [ Time Frame: At 12 months ] [ Designated as safety issue: No ]
• Bleeding intensity, dysmenorrhea, and user satisfaction (questionnaires completed by patient) [ Time Frame: Initial and after 3, 6, 12 and 24 months ] [ Designated as safety issue: No ]
• Cumulative discontinuation rate for unintended pregnancy, bleeding problems, other medical reasons, for non-medical reasons [ Time Frame: At 24 months ] [ Designated as safety issue: No ]
• Incidence of Adverse Events, Serious Adverse Events [ Time Frame: During 24 months ] [ Designated as safety issue: Yes ]
• The return to fertility of women discontinuing the method for wish for pregnancy [ Time Frame: 12 months after discontinuation ] [ Designated as safety issue: No ]

• Continuation rate [ Time Frame: During 12 months ] [ Designated as safety issue: No ]
• Bleeding intensity, dysmenorrhea, and user satisfaction [ Time Frame: Initial and after 3, 6, 12 and 24 months ] [ Designated as safety issue: No ]
• Cumulative discontinuation rate for unintended pregnancy [ Time Frame: During 24 months ] [ Designated as safety issue: No ]
• Cumulative discontinuation rate for bleeding problems [ Time Frame: During 24 months ] [ Designated as safety issue: No ]
• Cumulative discontinuation rate for other medical reasons [ Time Frame: During 24 months ] [ Designated as safety issue: No ]
• Cumulative discontinuation rate for non-medical reasons [ Time Frame: During 24 months ] [ Designated as safety issue: No ]
• Incidence of Adverse Events, Serious Adverse Events [ Time Frame: During 24 months ] [ Designated as safety issue: Yes ]
• The return to fertility of women discontinuing the method for wish for pregnancy [ Time Frame: 12 months after discontinuation ] [ Designated as safety issue: No ]

The study examines the use of Mirena or Implanon for long-term contraception in women. The duration of therapy use is the key focus of the study. Also, any reasons for discontinuation and the safety profile will be examined. In addition, patients are asked to fill out a short questionnaire about their menstrual bleeding before and during therapy.

Women aged 20-35 years switching from short-acting hormonal contraception

• Drug: Levonorgestrel IUS (Mirena, BAY86-5028)
  Patients under daily life treatment receiving Mirena according to local drug information.
• Drug: Implanon (Etonogestrel)
  Patients under daily life treatment receiving Implanon according to local drug information.

• Group 1
  Intervention: Drug: Levonorgestrel IUS (Mirena, BAY86-5028)
• Group 2
  Intervention: Drug: Implanon (Etonogestrel)

Inclusion Criteria:

• Women aged 20-35 in good general health requesting contraception
• Women who have used short-acting hormonal contraception (combined or progestogen-only pills, vaginal ring or contraceptive patch) for at least 3 cycles immediately before entering the study and opting to change to either Mirena or Implanon for contraception
• Women who have given a written informed consent to participate in the study (if applicable)

Exclusion Criteria:

• The contraindications and warnings of the respective Summary of Product Characteristics (Mirena or Implanon) must be followed. The decision to start Mirena or Implanon has to be made clearly before the decision to include patients in the study
• Patients who are breast-feeding at time of inclusion for the study will also be excluded since breast-feeding affects the bleeding pattern